Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
160
Employees160
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
160
Employees160

CAPR Key Statistics

Market cap
1.23B
Market cap1.23B
Price-Earnings ratio
-14.95
Price-Earnings ratio-14.95
Dividend yield
Dividend yield
Average volume
9.83M
Average volume9.83M
High today
$28.63
High today$28.63
Low today
$26.00
Low today$26.00
Open price
$26.72
Open price$26.72
Volume
7.04M
Volume7.04M
52 Week high
$40.37
52 Week high$40.37
52 Week low
$4.30
52 Week low$4.30

Stock Snapshot

With a market cap of 1.23B, Capricor(CAPR) trades at $26.79. The stock has a price-to-earnings ratio of -14.95.

As of 2025-12-07, Capricor(CAPR) stock has fluctuated between $26.00 and $28.63. The current price stands at $26.79, placing the stock +3.0% above today's low and -6.4% off the high.

Capricor(CAPR) shares are trading with a volume of 7.04M, against a daily average of 9.83M.

In the last year, Capricor(CAPR) shares hit a 52-week high of $40.37 and a 52-week low of $4.30.

In the last year, Capricor(CAPR) shares hit a 52-week high of $40.37 and a 52-week low of $4.30.

CAPR News

Nasdaq 1d
Capricor Therapeutics Price Target Increased by 84.54% to 38.96

The average one-year price target for Capricor Therapeutics (NasdaqCM:CAPR) has been revised to $38.96 / share. This is an increase of 84.54% from the prior est...

Capricor Therapeutics Price Target Increased by 84.54% to 38.96
TipRanks 1d
Capricor Therapeutics Announces $150 Million Public Offering

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

TipRanks 2d
Capricor Therapeutics announces common stock offering, no amount given

Capricor Therapeutics (CAPR) announced the commencement of a proposed underwritten public offering of shares of its common stock. The company intends to use the...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More CAPR News

Benzinga 4d
Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead...

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.